Cingulate Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Shane J. Schaffer
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1901 West 47th Place Kansas City KS United States of America 66205
- IPO Date
- Dec 8, 2021
- CIK
- 0001862150
- Website
- cingulate.com
- Similar Companies
- Business
- Cingulate Inc. is a biopharmaceutical company in the clinical stage, dedicated to developing innovative therapeutic candidates through its proprietary Precision Timed Release™ (PTR™) drug delivery platform. The company's primary focus lies in treatments for attention-deficit/hyperactivity disorder (ADHD) and anxiety. Its lead candidate, CTx-1301, a dexmethylphenidate formulation for ADHD, recently reported positive Phase 3 results in pediatric patients. Cingulate submitted a New Drug Application (NDA) for CTx-1301 to the FDA in July 2025, which the agency accepted for review in October 2025, setting a PDUFA target action date of May 31, 2026. Another ADHD product in its pipeline is CTx-1302 (dextroamphetamine), for which the company is currently preparing an Investigational New Drug (IND) application. For anxiety disorders, Cingulate is advancing CTx-2103, a buspirone-based candidate, which has completed its formulation study demonstrating triple-release capability and recently received grant funding to accelerate its development. The company, founded in 2012, is based in Kansas City, Kansas.
Company News
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
US FDA declines to approve Cingulate's ADHD drug
Cingulate Receives Complete Response Letter from FDA for CTx-1301
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
Why did Cingulate stock skyrocket today?
Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts
Cingulate Inc. (NASDAQ:CING) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Cingulate Provides Management Team Update
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301